Last updated
Amgen: Product Launch
European Commission approved Amgen's IMDYLLTRA® for extensive-stage small cell lung cancer treatment, demonstrating 40% reduction in death risk versus chemotherapy in Phase 3 trial
Source: PRN — Business Technology
- Who
- Amgen · Biotech & Pharma · United Kingdom & Ireland
- What happened
- European Commission approved Amgen's IMDYLLTRA® for extensive-stage small cell lung cancer treatment, demonstrating 40% reduction in death risk versus chemotherapy in Phase 3 trial
- When
- 2026-06-01
Market context: MitchelLake's Talent Market Index sits at 109.3 (Hot), up 7.6 on the prior month; EMEA hiring signal is running easing (-3.6pts).
Amgen: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 33 tracked companies; 0.1% of MitchelLake's EMEA signal flow; 4 tracked across 79 days.
MitchelLake in this thematic
Also at Amgen →
More signals across Biotech & Pharma
Product Launch · EMEA
AviadoBio →AviadoBio has presented Phase 1/2 trial data for AVB-101, its investigational gene therapy for frontotemporal dementia with GRN mutations (FTD-GRN), showing dose-dependent increases in cerebrospinal fluid progranulin levels across four ascending doses.
Product Launch · EMEA
Biogen Inc. →Biogen announced 52-week Phase 2 results for litifilimab in cutaneous lupus erythematosus (CLE), demonstrating rapid and durable efficacy. Data supports potential first-in-class therapy positioning. Results presented at EADV 2026 Congress in Vienna. Ongoing Phase 2/3 AMETHYST study progressing.
Product Launch · EMEA
Boehringer Ingelheim →Boehringer Ingelheim announced Phase III trial success for survodutide (BI 456906), a glucagon/GLP-1 receptor dual agonist, achieving 13.1% average weight loss in obesity and type 2 diabetes patients. Results published in NEJM and presented at EASD conference.
Product Launch · EMEA
Teva Pharmaceuticals →Teva Pharmaceuticals reported successful topline results from a gluten challenge study showing that a single injection of an experimental antibody significantly reduced intestinal damage in celiac disease patients who consumed gluten daily.
Product Launch · EMEA
Biogen →Biogen and Eisai gained FDA approval for LEQEMBI IQLIK, an at-home subcutaneous autoinjector for Alzheimer's treatment, plus Phase 2 data showing tau reduction with investigational therapy diranersen. Positions Biogen as leader in amyloid- and tau-targeting approaches.
Product Launch · EMEA
Bristol Myers Squibb →Bristol Myers Squibb reported positive Phase III clinical trial results for mezigdomide (multiple myeloma) and early-stage CAR T-cell therapy arlocabtagene autoleucel with strong response rates and manageable safety profiles, presented at European Hematology Association Congress 2026.
Where this lands in our work
- Product Technology Executive Search →
A launch is the output of a product and engineering leadership layer built before it.
- Executive Search: EMEA →
Our EMEA practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗
Nearby in the record